Clinical Trial Update: Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS [Phase 3]

View source ↗

Summary

Phase 3 study evaluating escitalopram (Lexapro) for generalized anxiety disorder in patients with HIV infection has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder
• HIV Infection

Drugs mentioned

• Lexapro (escitalopram)

Snippet

Sponsor: Duke University | Conditions: Anxiety Disorders, HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2014-03-10